Skip to content
Main Navigation
About us
Company profile
Our values
Our strategy
Board of directors
Senior Management
Our history
Innovation and research
Technology platform
Therapeutic areas
Scientific papers and presentations
Pipeline
Partnering
Our approach
Our partnerships
Investors
Financial reports and presentations
Share information
Analyst coverage
Major shareholders
Tax Value per Share
Financial calendar
Corporate governance
Corporate governance statements
ESG
Dividend policy
Annual general meeting
Articles of association
Safe harbour statement
Whistleblower policy
Risk management
Investor relations policy
Email alerting service
Media
News and announcements
Image library
Glossary
Careers
Life at Nykode
Meet us
Open positions
COVID trial
Search
Media
News and Announcements
Newest first
Oldest first
Announcements
News
Search
Reset
27/09/2022
Nykode Therapeutics Announces Positive Results from the Phase 1/2 Open Label, Dose Escalation Trial of its T Cell Focused SARS-CoV-2 Vaccine Candidate
12/09/2022
Nykode Therapeutics to present at H.C. Wainwright 24th Annual Global Investment Conference
08/09/2022
Nykode Therapeutics to be included in the Oslo Børs Benchmark Index (OSEBX) and the Oslo Børs Mutual Fund Index (OSEFX)
22/08/2022
Nykode Therapeutics to announce financial results for the first half of 2022 and host webcast presentation on August 24, 2022
16/06/2022
Nykode Therapeutics uplisted to the main list of the Oslo Stock Exchange
Pages:
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
Load more
Sorry, nothing found in this query
Privacy statement
Cookie policy
Disclaimer
